Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 8, 2012, Pages 1581-1590

  Gorczyca, M E ^a   Nair, S C ^b   Jilma, B ^a   Priya, S ^b   Male, C ^c   Reitter, S ^a   Knoebl, P ^a   Gilbert, J C ^d   Schaub, R G ^d   Dockal, M ^e   Mcginness, K E ^e   Pabinger, I ^a   Srivastava, A ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHRISTIAN MEDICAL COLLEGE   (India)

^c UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^d Archemix Corporation   (United States)

^e NONE

Author keywords

Aptamer; ARC19499; BAX499; Hemophilia; Thrombin generation; Tissue factor pathway inhibitor

Indexed keywords

APTAMER; BAX 499; PROTEIN INHIBITOR; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOMATION; BLOOD; CALIBRATION; CONCENTRATION (PARAMETERS); CONGENITAL DISORDER; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BINDING; EX VIVO STUDY; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOELASTOGRAPHY;

ADOLESCENT; ADULT; AGED; APTAMERS, NUCLEOTIDE; AUSTRIA; BLOOD COAGULATION; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOPHILIA A; HEMOPHILIA B; HEMOSTATICS; HUMANS; INDIA; LIPOPROTEINS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; THROMBELASTOGRAPHY; THROMBIN; WHOLE BLOOD COAGULATION TIME; YOUNG ADULT;

EID: 84865223913     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04790.x     Document Type: Article

References (42)

1. Plug I, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR, van der Bom JG. Social participation of patients with hemophilia in the Netherlands. Blood 2008; 111: 1811-15.
2. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 2009; 101: 674-81.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
4. Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia 2009; 15 (Suppl. 1): 2-7.
5. Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
6. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
7. Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Negrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zulfikar B, Mantovani L. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
8. Collins PW, Bjorkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
9. Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M, Santagostino E, Blanchette V. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 17: e849-57.
10. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
11. De Moerloose P, Urbancik W, Van den Berg HM, Richards M. A survey of adherence to haemophilia therapy in six European countries: results and recommendations. Haemophilia 2008; 14: 931-8.
12. Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res 2008; 122 (Suppl. 4): S2-8.
13. Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8: 421-32.
14. Hedner U. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost 2008; 100: 557-62.
15. Tiede A, Huth-Kuhne A, Oldenburg J, Grossmann R, Geisen U, Krause M, Brand B, Alberio L, Klamroth R, Spannagl M, Knobl P. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Ann Hematol 2009; 88: 365-70.
16. Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 9 (Suppl. 1): 226-35.
17. Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M, Santagostino E, Blanchette V. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 17: e849-57.
18. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
19. Welsch DJ, Novotny WF, Wun TC. Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas. Thromb Res 1991; 64: 213-22.
20. Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost 1991; 66: 464-7.
21. Prasad S, Lillicrap D, Labelle A, Knappe S, Keller T, Burnett E, Powell S, Johnson KW. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 2008; 111: 672-9.
22. Erhardtsen E, Ezban M, Madsen MT, Diness V, Glazer S, Hedner U, Nordfang O. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A. Blood Coagul Fibrinolysis 1995; 6: 388-94.
23. Mackman N. The role of tissue factor and factor VIIA in hemostasis. Anesth Analg 2009; 108: 1447-52.
24. Brinkmann T, Kahnert H, Prohaska W, Nordfang O, Kleesiek K. Synthesis of tissue factor pathway inhibitor in human synovial cells and chondrocytes makes joints the predilected site of bleeding in haemophiliacs. Eur J Clin Chem Clin Biochem 1994; 32: 313-17.
25. Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor. Blood 2011; 117: 5514-22.
26. Parunov LA, Fadeeva OA, Balandina AN, Soshitova NP, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA. Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation. J Thromb Haemost 2011; 9: 1825-34.
27. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010; 50: 237-57.
28. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008; 26: 442-9.
29. Spiel AO, Mayr FB, Firbas C, Quehenberger P, Jilma B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006; 4: 411-16.
30. Hartert H. Clinical studies on blood coagulation with thrombelastography I. Physiological and methodic basis of the method. Dtsch Arch Klin Med 1952; 199: 284-92.
31. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci 2012; 17: 262-80.
32. Jilma B, Dirnberger E, Eichler HG, Matulla B, Schmetterer L, Kapiotis S, Speiser W, Wagner OF. Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor VIII in man. Thromb Haemost 1997; 78: 1268-71.
33. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
34. Knobl P, Derfler K. Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 1999; 77 (Suppl. 1): 57-64.
35. Knobl P, Derfler K, Korninger L, Kapiotis S, Jager U, Maier-Dobersberger T, Horl W, Lechner K, Pabinger I. Elimination of acquired factor VIII antibodies by extracorporal antibody-based immunoadsorption (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-8.
36. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-92.
37. Mann KG, Whelihan MF, Butenas S, Orfeo T. Citrate anticoagulation and the dynamics of thrombin generation. J Thromb Haemost 2007; 5: 2055-61.
38. Chitlur M, Sorensen B, Rivard GE, Young G, Ingerslev J, Othman M, Nugent D, Kenet G, Escobar M, Lusher J. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia 2011; 17: 532-7.
39. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-33.
40. Warr TA, Warn-Cramer BJ, Rao LV, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I Standardization of assay and evaluation of physiologic variables. Blood 1989; 74: 201-6.
41. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knobl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost 2010; 104: 563-70.
42. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knobl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545-52.